Conflict of interest: Nothing to declare.
Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance
Version of Record online: 9 SEP 2013
© 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 61, Issue 4, pages 737–739, April 2014
How to Cite
Turcotte, L. M., Correll, C. K., Reed, R. C. and Moertel, C. L. (2014), Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr. Blood Cancer, 61: 737–739. doi: 10.1002/pbc.24761
- Issue online: 6 FEB 2014
- Version of Record online: 9 SEP 2013
- Manuscript Accepted: 12 AUG 2013
- Manuscript Received: 11 JUN 2013
- NIH T32. Grant Number: CA099936
- Children's Cancer Research Fund, Minneapolis, MN
- multicentric Castleman disease;
Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy. Pediatr Blood Cancer 2014;61:737–739. © 2013 Wiley Periodicals, Inc.